Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

Cubist augments position in antibiotic market with Trius and Optimer buys

Authored by Paul Foster Cubist Pharmaceuticals announced on 30th July 2013 that they had acquired 2 biopharmaceutical companies Trius Therapeutics Inc. and Optimer Pharmaceuticals Inc., both of whom are focussed on developing innovative antibiotics for serious infections treated within the … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , | Leave a comment

Inhalable gene therapy may aid PAH patients

Authored by James Sheppard US researchers have shown in a new study that gene therapy administered through a nebulizer-like inhalation device can completely reverse pulmonary arterial hypertension (PAH) in rat models of the disease. The research was conducted at The … Continue reading

Posted in Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , | Leave a comment

Isis gains milestone from GSK for rare disease trial and Aegerion takes them on in HoFH

Authored by Karl Simpson Isis Pharmaceuticals is developing a drug for the treatment of the rare diseases transthyretin amyloidosis. The disease is a severe and rare genetic disorder characterized by dysfunction of the peripheral nerve and/or heart tissues. The company … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , | Leave a comment

Liftstream invites Guest Bloggers

Liftstream would like to invite guest bloggers to contribute to our blog and newsletter on www.liftstream.com/blog. Liftstream invites articles on any area within the life science field. In particular, Liftstream would be interest in hearing the thoughts and opinions of … Continue reading

Posted in General, Job Hunting Advice, M&A Finance and Funding, Medical Device, Orphan Drugs and Rare Diseases, Pharmaceutical business, Recruitment Market, Workplace Diversity | Leave a comment

‘Large company man’…a role in start-ups?

Authored by Karl Simpson (A perspective from start-up world) ‘Large company man’ is an expression I’ve always viewed as an interesting one. What are people actually saying about the anointed person when they brand them in this way? Is it … Continue reading

Posted in Recruitment Market | Tagged , , , , , , , , , , , , , , | Leave a comment

Topotarget given Orphan designation for rare cancer therapy

Authored by Karl Simpson Copenhagen based Topotarget has been granted European Orphan Drug Designation (ODD) for belinostat for the treatment of malignant thymomas. Belinostat is a novel pan-HDAC inhibitor in late-stage clinical development with more than 1,100 patient treated. The … Continue reading

Posted in Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , | Leave a comment

Prosensa, Sarepta, PTC, Summit and DART all contribute to the ubiquity of news in Duchenne

Authored by James Sheppard The Duchenne Muscular Dystrophy market has seen considerable advances  in recent months, with companies Prosensa, PTC Therapeutics, Sarepta Therapeutics, Summit and considerable others announcing regular news on  funding, IPOs, research, clinical and regulatory. Prosensa, the Dutch … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 2 Comments

PAH franchise and cost cutting prevent Actelion from listing further

Authored by Karl Simpson Back in 2011, Elliott Advisors, a shareholder in Actelion, tried to mount a boardroom coup to unseat the CEO and install its own management. At the time they cited questions over the Company’s strategy and governance … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , | Leave a comment

EMA’s COMP appoints team to assess orphan application in dengue fever

Authored by Karl Simpson The Committee on Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has appointed a team of clinical coordinators for the purpose of reviewing NanoViricides pending orphan drug designation for DengueCide™, the Company’s drug product … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Esophageal cancer: Merrimack’s bispecific MM-111 moves to phase 2 and new HPV research

Authored by Karl Simpson Today has seen a couple of key announcements in the treatment of esophageal cancer. Firstly, Merrimack Pharmaceuticals announced the enrolment of its first patient in a Phase 2 clinical trial of its bispecific antibody, MM-111, for … Continue reading

Posted in Pharmaceutical business | Tagged , , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap